Janet MBA - Spyre Therapeutics Senior Operations
| SYRE Stock | 28.43 0.68 2.45% |
Executive
Janet MBA is Senior Operations of Spyre Therapeutics
| Address | 221 Crescent Street, Waltham, MA, United States, 02453 |
| Phone | 617 651 5940 |
| Web | https://www.spyre.com |
Spyre Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3881) % which means that it has lost $0.3881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9162) %, meaning that it created substantial loss on money invested by shareholders. Spyre Therapeutics' management efficiency ratios could be used to measure how well Spyre Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -1.04. In addition to that, Return On Capital Employed is expected to decline to -0.82. At present, Spyre Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 358.6 M, whereas Non Currrent Assets Other are forecasted to decline to 8,550.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ashraf Amanullah | Inhibrx | 56 | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Helen MD | Enliven Therapeutics | 61 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| David MBA | Inhibrx | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Bonne MBA | Inhibrx | 47 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Charbel PharmD | Inhibrx | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| Carlos Bais | Inhibrx | N/A | |
| Dr Esq | Enliven Therapeutics | 47 | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
Management Performance
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 |
Spyre Therapeutics Leadership Team
Elected by the shareholders, the Spyre Therapeutics' board of directors comprises two types of representatives: Spyre Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spyre. The board's role is to monitor Spyre Therapeutics' management team and ensure that shareholders' interests are well served. Spyre Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spyre Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, Consultant | ||
| Janet MBA, Senior Operations | ||
| Eric McIntyre, Vice Relations | ||
| Cameron DPHIL, Principal CEO | ||
| Deanna MD, Senior Development | ||
| CFE CPA, Vice Controller | ||
| Justin LaFountaine, Senior Development | ||
| Paul JD, Senior Counsel | ||
| Melissa Cooper, Senior People | ||
| LLM JD, Chief Secretary | ||
| Brian Connolly, Chief Officer | ||
| Scott Burrows, Chief Officer | ||
| Kelly Boothe, Senior Relations | ||
| James Myers, Vice Compliance | ||
| MiRa Huyghe, Senior Operations | ||
| Andrew Spencer, Senior Development | ||
| Joshua MD, Senior Development |
Spyre Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spyre Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 58.71 M | ||||
| Shares Owned By Insiders | 8.80 % | ||||
| Shares Owned By Institutions | 88.38 % | ||||
| Number Of Shares Shorted | 8.04 M | ||||
| Price To Book | 9.73 X | ||||
| Price To Sales | 2,210 X | ||||
| Revenue | 886 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.